PDIA4 and glioblastoma: The results indicated that BEV therapy did not influence VEGFA in GBM or in its microenvironment as no significant differences were observed between TMZ monotherapy and TMZ and BEV combination therapy in both the GBM subgroups LV-Ctrl and LV-PDIA4 (Fig. 6H-I).